@article{bb66623c9ed547e08b80508875a391f5,
title = "Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension",
abstract = "We evaluate the effect of droxidopa on gait and balance measures in nine patients with Parkinson's disease and neurogenic orthostatic hypotension. Computerized gait/balance analysis showed a significant effect of droxidopa in reducing postural sway. Future studies may determine if such effect translates into improvement in postural reflexes and falls.",
keywords = "Droxidopa, Orthostatic hypotension, Parkinson disease, Postural sway, Wearables",
author = "Luca Marsili and Duque, {Kevin R.} and Andrea Sturchio and Gabriele Sobrero and Isabella Premoli and Dwivedi, {Alok K.} and Espay, {Alberto J.} and Aristide Merola",
note = "Funding Information: The study was sponsored by Lundbeck. Kevin R. Duque and Gabriele Sobrero declare no competing interests. Luca Marsili has received honoraria from the International Association of Parkinsonism and Related Disorders (IAPRD) Society for social media and web support. Andrea Sturchio is cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies. Isabella Premoli is an employee of Lundbeck, who funded the study. Alok K. Dwivedi has been serving as a co-investigator in grants funded by CPRIT and NIH. He is a director of the Biostatistics and Epidemiology Consulting lab at Texas Tech University Health Sciences Center at El Paso, an associate editor of Journal of Investigative Medicine, and has an adjunct appointment in the Department of Neurology & Rehabilitation Medicine, University of Cincinnati, Ohio. Alberto J. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Neurocrine, Amneal, Acadia, Acorda, Bexion, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), Avion Pharmaceuticals, and Herantis Pharma; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics (a biotech start-up developing nonaggregating peptide analogues as replacement therapies for neurodegenerative diseases) and is co-owner of a patent that covers synthetic soluble nonaggregating peptide analogues as replacement treatments in proteinopathies. Aristide Merola has received speaker honoraria from Abbott Laboratories, Abbvie, and Boston Scientific. He has received grant support from Lundbeck and Abbvie. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
month = jun,
doi = "10.1016/j.parkreldis.2022.05.002",
language = "English",
volume = "99",
pages = "62--64",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier",
}